Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Intellia Therapeutics Inc's Business Segments
Intellia Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
$ 8
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 23 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 23 | - |
Description of Intellia Therapeutics Inc
Intellia Therapeutics Inc. is a biotechnology company focused on developing revolutionary genome editing technologies to treat genetic diseases. Founded in 2014, the company is headquartered in Cambridge, Massachusetts, United States.
Intellia Therapeutics is widely known for its expertise in CRISPR/Cas9 gene editing technology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring system found in bacterial immune systems that allows precise editing of genes. Intellia Therapeutics has harnessed this technology to develop therapeutic strategies to modify the DNA of cells with the aim of correcting or eliminating the underlying genetic causes of diseases.
The company's research primarily revolves around developing CRISPR/Cas9 as a powerful tool to selectively modify target genes in a precise and specific manner. Intellia Therapeutics aims to leverage this technology to develop one-time treatments for genetic diseases that have been historically challenging to treat.
Intellia Therapeutics’ therapeutic pipeline is focused on three areas: in vivo editing, ex vivo editing, and engineered cell therapies. In vivo editing refers to editing genes within the body, while ex vivo editing involves modifying genes in cells outside the body before reintroduction to the patient. Engineered cell therapies involve genetically modifying cells to enhance their therapeutic potential.
The company has collaborated with various partners, including Regeneron Pharmaceuticals, Novartis, and Ospedale San Raffaele, to advance its research and development efforts. Through these partnerships, Intellia Therapeutics has been able to combine its gene editing technology with the expertise of its collaborators to accelerate the development of novel therapies.
In terms of its clinical pipeline, Intellia Therapeutics is actively developing multiple programs for the treatment of genetic diseases. The company's lead program is focused on the development of a potential treatment for transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the buildup of abnormal protein deposits in various tissues and organs.
Apart from ATTR, Intellia Therapeutics is also exploring the application of its technology in treating other diseases such as hereditary angioedema (HAE), acute myeloid leukemia (AML), and sickle cell disease, among others.
In addition to its therapeutic programs, Intellia Therapeutics is committed to advancing the field of gene editing by actively investing in research and development activities. The company aims to improve the efficiency and specificity of its gene editing technologies and expand their applicability to a wider range of diseases.
As a company at the forefront of gene editing technology, Intellia Therapeutics places a strong emphasis on ensuring the safety and ethical use of its technologies. The company adheres to strict regulatory guidelines and ethical standards to ensure that its therapies are developed and deployed in a responsible and beneficial manner.
Overall, Intellia Therapeutics is a leading biotechnology company that leverages CRISPR/Cas9 technology to develop innovative therapies for genetic diseases. With its extensive research and development efforts, strategic partnerships, and commitment to ethical practices, the company is poised to pave the way for groundbreaking advancements in the field of gene editing.
Intellia Therapeutics is widely known for its expertise in CRISPR/Cas9 gene editing technology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring system found in bacterial immune systems that allows precise editing of genes. Intellia Therapeutics has harnessed this technology to develop therapeutic strategies to modify the DNA of cells with the aim of correcting or eliminating the underlying genetic causes of diseases.
The company's research primarily revolves around developing CRISPR/Cas9 as a powerful tool to selectively modify target genes in a precise and specific manner. Intellia Therapeutics aims to leverage this technology to develop one-time treatments for genetic diseases that have been historically challenging to treat.
Intellia Therapeutics’ therapeutic pipeline is focused on three areas: in vivo editing, ex vivo editing, and engineered cell therapies. In vivo editing refers to editing genes within the body, while ex vivo editing involves modifying genes in cells outside the body before reintroduction to the patient. Engineered cell therapies involve genetically modifying cells to enhance their therapeutic potential.
The company has collaborated with various partners, including Regeneron Pharmaceuticals, Novartis, and Ospedale San Raffaele, to advance its research and development efforts. Through these partnerships, Intellia Therapeutics has been able to combine its gene editing technology with the expertise of its collaborators to accelerate the development of novel therapies.
In terms of its clinical pipeline, Intellia Therapeutics is actively developing multiple programs for the treatment of genetic diseases. The company's lead program is focused on the development of a potential treatment for transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the buildup of abnormal protein deposits in various tissues and organs.
Apart from ATTR, Intellia Therapeutics is also exploring the application of its technology in treating other diseases such as hereditary angioedema (HAE), acute myeloid leukemia (AML), and sickle cell disease, among others.
In addition to its therapeutic programs, Intellia Therapeutics is committed to advancing the field of gene editing by actively investing in research and development activities. The company aims to improve the efficiency and specificity of its gene editing technologies and expand their applicability to a wider range of diseases.
As a company at the forefront of gene editing technology, Intellia Therapeutics places a strong emphasis on ensuring the safety and ethical use of its technologies. The company adheres to strict regulatory guidelines and ethical standards to ensure that its therapies are developed and deployed in a responsible and beneficial manner.
Overall, Intellia Therapeutics is a leading biotechnology company that leverages CRISPR/Cas9 technology to develop innovative therapies for genetic diseases. With its extensive research and development efforts, strategic partnerships, and commitment to ethical practices, the company is poised to pave the way for groundbreaking advancements in the field of gene editing.
Intellia Therapeutics Inc. is a pioneering biotechnology company focused on leveraging its proprietary CRISPR/Cas9 gene-editing technology to develop revolutionary therapies for various genetic diseases. The companys work encompasses a range of segments, products, and services that primarily revolve around gene editing and therapeutic development. Below is an extensive description of these elements.
Segments
1. Gene Editing Technology:
- Intellia is renowned for its CRISPR/Cas9 platform, which enables precise alterations to the DNA of living organisms. This technology allows for the modification, deletion, or insertion of genetic material, addressing a wide array of genetic disorders at their source.
2. Therapeutics Development:
- The company focuses on creating novel therapeutics aimed at treating rare and common genetic diseases through their gene-editing capabilities. These therapies are designed to provide long-term or potentially curative solutions rather than mere symptomatic treatments.
3. Collaboration and Partnerships:
- Intellia often collaborates with academic institutions and other biotech/pharmaceutical companies to expand the applications of its technologies. These partnerships are pivotal in the sharing of knowledge, resources, and networks to accelerate the development of promising therapies.
4. Research and Development (R&D):
- A significant segment of Intellias operations is committed to R&D, where the company invests heavily in preclinical and clinical trials to validate the efficacy and safety of its gene-editing technologies and therapeutic candidates.
Products
1. NTLA-2001:
- This is the company’s lead product candidate for the treatment of transthyretin (ATTR) amyloidosis, a progressive disease caused by the buildup of amyloid proteins. NTLA-2001 aims to provide a one-time treatment that could potentially silence the mutated gene responsible for the disease.
2. NTLA-3001:
- Targeting hereditary angioedema, NTLA-3001 uses the CRISPR technology to knock out the gene responsible for the overproduction of bradykinin, thereby alleviating the symptoms associated with this genetic condition.
3. NTLA-2002:
- NTLA-2002 is being developed for the treatment of various hematological disorders, including sickle cell disease and beta-thalassemia. The goal is to correct the underlying genetic defects in patients stem cells and provide potentially curative outcomes.
4. NTLA-4001:
- This product candidate focuses on utilizing gene editing to treat T-cell malignancies. It is designed to enhance the immune response against cancer cells by editing patient-derived T-cells.
Services
1. Clinical Development Services:
- Intellia engages in extensive clinical trial processes to demonstrate the safety and efficacy of its therapeutic candidates. This includes Phase 1 and Phase 2 trials, patient recruitment, data management, and regulatory interactions.
2. Research Collaborations:
- The company offers collaborative services with academic institutions and pharmaceutical partners, enabling the exploration of new therapeutic avenues using CRISPR technology.
3. Technology Licensing:
- Intellia may offer licensing agreements for their CRISPR/Cas9 technology to other biotech firms, allowing them to utilize the patented gene-editing techniques in their own drug development processes.
4. Consulting Services:
- The firm may also provide consulting services to other entities interested in understanding the practical applications and implications of CRISPR technology for their research and development projects.
Summary
Intellia Therapeutics Inc. stands at the forefront of gene editing technology, with a clear focus on developing transformative therapies for a range of genetic diseases. Through its proprietary CRISPR/Cas9 platform, the company is not only advancing its pipeline of innovative products but also providing essential services that drive the broader application and integration of gene-editing technologies in medicine. These contributions are aimed at producing meaningful, long-lasting healthcare solutions for patients afflicted by genetic disorders.
Segments
1. Gene Editing Technology:
- Intellia is renowned for its CRISPR/Cas9 platform, which enables precise alterations to the DNA of living organisms. This technology allows for the modification, deletion, or insertion of genetic material, addressing a wide array of genetic disorders at their source.
2. Therapeutics Development:
- The company focuses on creating novel therapeutics aimed at treating rare and common genetic diseases through their gene-editing capabilities. These therapies are designed to provide long-term or potentially curative solutions rather than mere symptomatic treatments.
3. Collaboration and Partnerships:
- Intellia often collaborates with academic institutions and other biotech/pharmaceutical companies to expand the applications of its technologies. These partnerships are pivotal in the sharing of knowledge, resources, and networks to accelerate the development of promising therapies.
4. Research and Development (R&D):
- A significant segment of Intellias operations is committed to R&D, where the company invests heavily in preclinical and clinical trials to validate the efficacy and safety of its gene-editing technologies and therapeutic candidates.
Products
1. NTLA-2001:
- This is the company’s lead product candidate for the treatment of transthyretin (ATTR) amyloidosis, a progressive disease caused by the buildup of amyloid proteins. NTLA-2001 aims to provide a one-time treatment that could potentially silence the mutated gene responsible for the disease.
2. NTLA-3001:
- Targeting hereditary angioedema, NTLA-3001 uses the CRISPR technology to knock out the gene responsible for the overproduction of bradykinin, thereby alleviating the symptoms associated with this genetic condition.
3. NTLA-2002:
- NTLA-2002 is being developed for the treatment of various hematological disorders, including sickle cell disease and beta-thalassemia. The goal is to correct the underlying genetic defects in patients stem cells and provide potentially curative outcomes.
4. NTLA-4001:
- This product candidate focuses on utilizing gene editing to treat T-cell malignancies. It is designed to enhance the immune response against cancer cells by editing patient-derived T-cells.
Services
1. Clinical Development Services:
- Intellia engages in extensive clinical trial processes to demonstrate the safety and efficacy of its therapeutic candidates. This includes Phase 1 and Phase 2 trials, patient recruitment, data management, and regulatory interactions.
2. Research Collaborations:
- The company offers collaborative services with academic institutions and pharmaceutical partners, enabling the exploration of new therapeutic avenues using CRISPR technology.
3. Technology Licensing:
- Intellia may offer licensing agreements for their CRISPR/Cas9 technology to other biotech firms, allowing them to utilize the patented gene-editing techniques in their own drug development processes.
4. Consulting Services:
- The firm may also provide consulting services to other entities interested in understanding the practical applications and implications of CRISPR technology for their research and development projects.
Summary
Intellia Therapeutics Inc. stands at the forefront of gene editing technology, with a clear focus on developing transformative therapies for a range of genetic diseases. Through its proprietary CRISPR/Cas9 platform, the company is not only advancing its pipeline of innovative products but also providing essential services that drive the broader application and integration of gene-editing technologies in medicine. These contributions are aimed at producing meaningful, long-lasting healthcare solutions for patients afflicted by genetic disorders.